cilostazol has been researched along with Brain Hemorrhage in 8 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "During the clinical follow-up, ischemic stroke recurred in 2 patients in cilostazol group, while in aspirin group, one case of ischemic stroke recurrence and one case of acute myocardial infarction were found." | 9.14 | Effect of cilostazol on cerebral arteries in secondary prevention of ischemic stroke. ( Guo, JJ; Lin, QY; Xie, HF; Xu, E; Zeng, GL, 2009) |
| "Background and Purpose- We performed a systematic review and meta-analysis to explore the efficacy and safety of cilostazol as a mono or combination (plus aspirin or clopidogrel) treatments compared to conventional single antiplatelet therapy (SAPT, mainly aspirin) for secondary stroke prevention." | 9.01 | Cilostazol Mono and Combination Treatments in Ischemic Stroke: An Updated Systematic Review and Meta-Analysis. ( Jung, JM; Kim, BJ; Kim, SM; Kwon, SU; Lee, JS, 2019) |
| "The Cilostazol Stroke Prevention Study 2 (CSPS 2) showed that cilostazol significantly reduced the risk of stroke by 25." | 7.80 | Benefit of cilostazol in patients with high risk of bleeding: subanalysis of cilostazol stroke prevention study 2. ( Genka, C; Hamada, C; Handa, S; Katayama, Y; Kitagawa, Y; Koretsune, Y; Kusuoka, H; Matsuoka, K; Nishimaru, K; Ohashi, Y; Sawada, T; Shinohara, Y; Tanahashi, N; Tsushima, M; Uchiyama, S; Yamaguchi, T; Yamamoto, H, 2014) |
| " As for intracranial hemorrhage (ICH), stroke recurrence, and adverse event (AE) rate, there were no significant differences of efficacy among 7 drug therapies." | 6.58 | Aspirin plus dipyridamole has the highest surface under the cumulative ranking curves (SUCRA) values in terms of mortality, intracranial hemorrhage, and adverse event rate among 7 drug therapies in the treatment of cerebral infarction. ( Liu, X; Zhang, JJ, 2018) |
| "During the clinical follow-up, ischemic stroke recurred in 2 patients in cilostazol group, while in aspirin group, one case of ischemic stroke recurrence and one case of acute myocardial infarction were found." | 5.14 | Effect of cilostazol on cerebral arteries in secondary prevention of ischemic stroke. ( Guo, JJ; Lin, QY; Xie, HF; Xu, E; Zeng, GL, 2009) |
| " Randomized clinical trials that compared cilostazol to aspirin and reported the endpoints of ischemic stroke, intracranial hemorrhage and any bleeding were included." | 5.12 | Cilostazol Versus Aspirin for Secondary Stroke Prevention: Systematic Review and Meta-Analysis. ( Barrett, KM; Brott, TG; Ertekin-Taner, N; Gopal, N; Lin, MP; Meschia, JF; Ross, OA, 2021) |
| "Background and Purpose- We performed a systematic review and meta-analysis to explore the efficacy and safety of cilostazol as a mono or combination (plus aspirin or clopidogrel) treatments compared to conventional single antiplatelet therapy (SAPT, mainly aspirin) for secondary stroke prevention." | 5.01 | Cilostazol Mono and Combination Treatments in Ischemic Stroke: An Updated Systematic Review and Meta-Analysis. ( Jung, JM; Kim, BJ; Kim, SM; Kwon, SU; Lee, JS, 2019) |
| "The Cilostazol Stroke Prevention Study 2 (CSPS 2) showed that cilostazol significantly reduced the risk of stroke by 25." | 3.80 | Benefit of cilostazol in patients with high risk of bleeding: subanalysis of cilostazol stroke prevention study 2. ( Genka, C; Hamada, C; Handa, S; Katayama, Y; Kitagawa, Y; Koretsune, Y; Kusuoka, H; Matsuoka, K; Nishimaru, K; Ohashi, Y; Sawada, T; Shinohara, Y; Tanahashi, N; Tsushima, M; Uchiyama, S; Yamaguchi, T; Yamamoto, H, 2014) |
| " As for intracranial hemorrhage (ICH), stroke recurrence, and adverse event (AE) rate, there were no significant differences of efficacy among 7 drug therapies." | 2.58 | Aspirin plus dipyridamole has the highest surface under the cumulative ranking curves (SUCRA) values in terms of mortality, intracranial hemorrhage, and adverse event rate among 7 drug therapies in the treatment of cerebral infarction. ( Liu, X; Zhang, JJ, 2018) |
| "Stroke is the second cause of mortality worldwide, and intravenous administration of tissue plasminogen activator (t-PA) within 3 h of symptom onset is the only treatment proven effective for re-establishment of cerebral blood flow following acute ischemic stroke." | 2.47 | Novel situations of endothelial injury in stroke--mechanisms of stroke and strategy of drug development: protective effects of antiplatelet agents against stroke. ( Hara, H; Shimazawa, M, 2011) |
| "Cilostazol is an antiplatelet agent that can induce the regression of atherosclerosis." | 1.40 | Carotid plaque characteristics on magnetic resonance plaque imaging following long-term cilostazol therapy. ( Narumi, S; Ohba, H; Oura, K; Sasaki, M; Terayama, Y; Uwano, I; Yamaguchi Oura, M, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 6 (75.00) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Kim, SM | 1 |
| Jung, JM | 1 |
| Kim, BJ | 1 |
| Lee, JS | 1 |
| Kwon, SU | 1 |
| Lin, MP | 1 |
| Meschia, JF | 1 |
| Gopal, N | 1 |
| Barrett, KM | 1 |
| Ross, OA | 1 |
| Ertekin-Taner, N | 1 |
| Brott, TG | 1 |
| Imai, T | 1 |
| Matsukawa, H | 1 |
| Takagi, T | 1 |
| Tsuruma, K | 1 |
| Shimazawa, M | 2 |
| Hara, H | 2 |
| Zhang, JJ | 1 |
| Liu, X | 1 |
| Uchiyama, S | 1 |
| Shinohara, Y | 1 |
| Katayama, Y | 1 |
| Yamaguchi, T | 1 |
| Handa, S | 1 |
| Matsuoka, K | 1 |
| Ohashi, Y | 1 |
| Tanahashi, N | 1 |
| Yamamoto, H | 1 |
| Genka, C | 1 |
| Kitagawa, Y | 1 |
| Kusuoka, H | 1 |
| Nishimaru, K | 1 |
| Tsushima, M | 1 |
| Koretsune, Y | 1 |
| Sawada, T | 1 |
| Hamada, C | 1 |
| Yamaguchi Oura, M | 1 |
| Sasaki, M | 1 |
| Ohba, H | 1 |
| Narumi, S | 1 |
| Oura, K | 1 |
| Uwano, I | 1 |
| Terayama, Y | 1 |
| Guo, JJ | 1 |
| Xu, E | 1 |
| Lin, QY | 1 |
| Zeng, GL | 1 |
| Xie, HF | 1 |
4 reviews available for cilostazol and Brain Hemorrhage
| Article | Year |
|---|---|
Cilostazol Mono and Combination Treatments in Ischemic Stroke: An Updated Systematic Review and Meta-Analysis.
Topics: Aspirin; Brain Ischemia; Cilostazol; Clopidogrel; Drug Therapy, Combination; Humans; Intracranial He | 2019 |
Cilostazol Versus Aspirin for Secondary Stroke Prevention: Systematic Review and Meta-Analysis.
Topics: Aged; Anti-Inflammatory Agents; Aspirin; Cilostazol; Female; Humans; Intracranial Hemorrhages; Ische | 2021 |
Aspirin plus dipyridamole has the highest surface under the cumulative ranking curves (SUCRA) values in terms of mortality, intracranial hemorrhage, and adverse event rate among 7 drug therapies in the treatment of cerebral infarction.
Topics: Aspirin; Cerebral Infarction; Cilostazol; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Hema | 2018 |
Novel situations of endothelial injury in stroke--mechanisms of stroke and strategy of drug development: protective effects of antiplatelet agents against stroke.
Topics: Animals; Blood-Brain Barrier; Brain Ischemia; Cilostazol; Endothelium, Vascular; Humans; Intracrania | 2011 |
1 trial available for cilostazol and Brain Hemorrhage
| Article | Year |
|---|---|
Effect of cilostazol on cerebral arteries in secondary prevention of ischemic stroke.
Topics: Aspirin; Blood Flow Velocity; Brain; Brain Ischemia; Cerebral Angiography; Cerebral Arteries; Cerebr | 2009 |
3 other studies available for cilostazol and Brain Hemorrhage
| Article | Year |
|---|---|
The phosphodiesterase III inhibitor cilostazol protects the brain microvasculature from collagenase injury.
Topics: Administration, Oral; Animals; Brain; Cardiovascular Agents; Cells, Cultured; Cilostazol; Collagen T | 2017 |
Benefit of cilostazol in patients with high risk of bleeding: subanalysis of cilostazol stroke prevention study 2.
Topics: Cilostazol; Humans; Intracranial Hemorrhages; Platelet Aggregation Inhibitors; Risk Factors; Stroke; | 2014 |
Carotid plaque characteristics on magnetic resonance plaque imaging following long-term cilostazol therapy.
Topics: Aged; Carotid Artery Diseases; Cilostazol; Female; Fibrosis; Humans; Imaging, Three-Dimensional; Int | 2014 |